Brief: Akeso Presented Promising Results Of Cadonilimab And Lenvatinib In Combination With Tace In Uhcc At 2024 Asco Gi
23/01/2024 13:29
Jan 23 (Reuters) - Akeso Inc 9926.HK :
* AKESO PRESENTED PROMISING RESULTS OF CADONILIMAB AND
LENVATINIB
IN COMBINATION WITH TACE IN UHCC AT 2024 ASCO GI
Source text for Eikon: ID:nPn5M07qna
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals